---
figid: PMC8834185__cells-11-00518-g002
figtitle: Cytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in
  Melanoma
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8834185
filename: cells-11-00518-g002.jpg
figlink: /pmc/articles/PMC8834185/figure/cells-11-00518-f002/
number: F2
caption: Cytoskeletal remodelling and hyperactivation in RAC1P29S-driven melanomas.
  RAC1P29S and BRAFV600E mutations frequently co-occur. Despite the efficacy of MAPK-targeted
  therapy, some cells can adapt and develop resistance, bypassing MAPK pathway blockade.
  Elevated RACP29Ssignalling plays a major role in this process, coordinating different
  downstream effectors. Some therapy resistance-promoting pathways are shared in BRAFV600E-
  and RAC1P29S-driven melanomas (integrin-PI3K-AKT), yet the roles of others, such
  as NMII activity, remain to be tested. RAC1P29S also promotes the expression of
  PD-L1, suggesting a possible link to immune evasion and ICB resistance.
papertitle: Cytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in
  Melanoma.
reftext: Adrian Barreno, et al. Cells. 2022 Feb;11(3):518.
year: '2022'
doi: 10.3390/cells11030518
journal_title: Cells
journal_nlm_ta: Cells
publisher_name: MDPI
keywords: melanoma | targeted therapy | resistance | cytoskeleton | actomyosin
automl_pathway: 0.8876312
figid_alias: PMC8834185__F2
figtype: Figure
redirect_from: /figures/PMC8834185__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8834185__cells-11-00518-g002.html
  '@type': Dataset
  description: Cytoskeletal remodelling and hyperactivation in RAC1P29S-driven melanomas.
    RAC1P29S and BRAFV600E mutations frequently co-occur. Despite the efficacy of
    MAPK-targeted therapy, some cells can adapt and develop resistance, bypassing
    MAPK pathway blockade. Elevated RACP29Ssignalling plays a major role in this process,
    coordinating different downstream effectors. Some therapy resistance-promoting
    pathways are shared in BRAFV600E- and RAC1P29S-driven melanomas (integrin-PI3K-AKT),
    yet the roles of others, such as NMII activity, remain to be tested. RAC1P29S
    also promotes the expression of PD-L1, suggesting a possible link to immune evasion
    and ICB resistance.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Cd274
  - Pak2
  - Pak1
  - Pkn1
  - Mdk
  - Ephb2
  - Mapk1
  - Myl2
  - Mylpf
  - Angptl6
  - Actr3
  - Apobec3
  - Aicda
  - Angptl2
  - Actr2
  - Srf
  - Kdm5d
  - Hya
  - CD274
  - PAK2
  - PKN2
  - PAK1
  - PKN1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - MYL2
  - MYL9
  - MYH14
  - MYO6
  - MYO10
  - MYO16
  - MYO19
  - MYH1
  - MYH10
  - MYH11
  - MYH13
  - MYH15
  - MYH16
  - MYH2
  - MYH3
  - MYH4
  - MYH6
  - MYH7
  - MYH7B
  - MYH8
  - MYH9
  - MYO1A
  - MYO1B
  - MYO1C
  - MYO1D
  - MYO1E
  - MYO1F
  - MYO1G
  - MYO1H
  - MYO3A
  - MYO3B
  - MYO5A
  - MYO5B
  - MYO5C
  - MYO7A
  - MYO7B
  - MYO9A
  - MYO9B
  - MYO15A
  - MYO15B
  - MYO18A
  - MYO18B
  - MYL1
  - MYL3
  - MYL4
  - MYL6
  - MYL6B
  - MYL10
  - MYL12A
  - MYL12B
  - MYL5
  - MYL7
  - MYL11
  - ACTR3
  - APOBEC3A
  - ACTR2
  - ANGPTL2
  - AICDA
  - SRF
  - mbt
  - Pak
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - Mlc2
  - CG17770
  - sqh
  - Mhc
  - zip
  - Arp3
  - Arp2
  - mal
  - bs
  - Mrtf
  - hy
---
